24/7 Market News Snapshot 06 June, 2025 – UroGen Pharma Ltd. Ordinary Shares (NASDAQ:URGN)

June 6, 2025

DENVER, Colo., 06 June, 2025 (www.247marketnews.com) – (NASDAQ:URGN) are discussed in this article.
UroGen Pharma Ltd. (URGN) has witnessed considerable market activity, opening at $5.33 and rising to approximately $5.79, marking an increase of about 12.65%. This surge follows a prior close of $5.14, indicating a strong bullish sentiment among investors. Trading volume has reached 2.85 million shares, signaling heightened interest and potential investor confidence in UroGen’s developments. The stock’s position above its previous support level suggests the possibility of continued upward momentum, with traders encouraged to monitor volume trends to confirm the sustainability of this price activity.

Simultaneously, The Law Offices of Frank R. Cruz have initiated a securities fraud class action lawsuit on behalf of investors affected by UroGen Pharma. This action highlights allegations that between July 27, 2023, and May 15, 2025, the company misrepresented the efficacy of its product, UGN-102, particularly in relation to the ENVISION clinical study design. The lawsuit asserts that the study’s lack of a concurrent control arm fundamentally compromises its validity, raising serious concerns regarding the future approval of UGN-102’s new drug application (NDA). Furthermore, it is alleged that UroGen disregarded critical feedback from the FDA regarding the study design, significantly increasing uncertainty around the company’s operational viability.

As investors experienced substantial losses due to these undisclosed risks, the law firm invites those impacted to participate by joining the class action lawsuit before the July 28, 2025 deadline. This legal initiative aims to hold UroGen accountable and protect investors’ rights, emphasizing the importance of transparency in the pharmaceutical industry. As the case unfolds, further details will be provided to facilitate affected investors in seeking justice and potential compensation for their losses.

Related news for (URGN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.